Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to ...

The options have an exercise price of $7.50 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments ...

The Coalition of Domestic Election Observers (CODEO) has implored electorates to refuse any inducements from political ...

Backblaze, Inc. (Nasdaq: BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, ...

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of ...

INOVIO (NASDAQ: INO) has announced a stock option grant to a newly hired employee under its 2022 Inducement Plan. The award ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm ...

The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635 (c) (4). The options have an exercise price of $10.

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, ...